Drug repurposing and discovery multidisciplinary training network

Drug repurposing (or repositioning) is the application of previously identified drugs or compounds to treat new indications. DRUGtrain offers a timely paradigm for multidisciplinary research on the improvement of drug repurposing and the development strategies of compounds, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) as example.

Identifying compounds for repurposing requires a broad variety of approaches: integration of molecular and pharmacological data, translation of fundamental research questions to the (pre)clinic and vice versa.

The DRUGtrain project aims to:

  1. Identify potential drug targets and drug candidates for repurposing using innovative bio-informatics and cheminformatics approaches;
  2. Perform drug testing/drug screenings in advanced in vitro and in vivo models, ultimately leading to testing of new treatment strategies;
  3. Clarify drug mechanisms, and identify and reduce adverse events using state-of-the-art technologies from in silico and wet lab methodologies.

Six universities, four private sector companies and one NGO will join forces to train a next generation of multidisciplinary researchers in biomedical and (bio)pharmaceutical sciences.

Current vacancies

1. USC (ES), ESR5: USC website, Euraxess (closing date: 15 June 2021)

2. LUMC (NL), ESR2: LUMC website, Euraxess (closing date: 27 June 2021)

3. OcellO (NL), ESR3: OcellO website, Euraxess (closing date: 28 June 2021

4. UKON (DE), ESR6: UKON website, Euraxess (closing date: 30 June 2021)

5. UKA (DE), ESR9: UKA website, Euraxess (closing date 1 August 2021)








DRUGtrain is an Initial Training Network, funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 955879.